Reports suggest AstraZeneca and Bristol Myers Squibb are considering a potential tie-up, in a deal that could create one of the world’s largest pharmaceutical companies, with a combined value of nearly $400bn.
If the transaction were to happen, it would be one of the largest deals of all time and, as such, only a limited number of law firms have the track record and global capability to lead.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact [email protected]
